


## PUBLISHER CORRECTION OPEN

## Publisher Correction: Mathematical model of hemodynamic mechanisms and consequences of glomerular hypertension in diabetic mice

Hari Shankar Mahato <sup>1</sup>, Christine Ahlstrom<sup>2</sup>, Rasmus Jansson-Löfmark<sup>2</sup>, Ulrika Johansson<sup>3</sup>, Gabriel Helmlinger<sup>4</sup> and K. Melissa Hallow<sup>1</sup>

*npj Systems Biology and Applications* (2019)5:9; <https://doi.org/10.1038/s41540-019-0081-8>

**Correction to:** *npj Systems Biology and Applications* <https://doi.org/10.1038/s41540-018-0077-9>, Published online 10 December 2018.

The original version of this Article had an incorrect Article number of 2, an incorrect Volume of 5 and an incorrect Publication year of 2019. These errors have now been corrected in the PDF and HTML versions of the Article.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

<sup>1</sup>School of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, GA, USA; <sup>2</sup>Drug Metabolism and Pharmacokinetics, Cardiovascular, Renal, and Metabolism, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, Sweden; <sup>3</sup>Bioscience Chronic Kidney Disease, Cardiovascular, Renal, and Metabolism Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, Sweden and <sup>4</sup>Quantitative Clinical Pharmacology, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Waltham, MA, USA  
Correspondence: K Melissa Hallow (hallowkm@uga.edu)

Published online: 04 March 2019